The ibs.GRANADA participates in a leading European project on personalized medicine

El European project U-PGx (Ubiquitous Pharmacogenomics), managed by FIBAO and where ibs.GRANADA researchers participate, implements the choice of drug treatment based on the genotyping of a panel of genetic markers and investigates whether this approach is cost-effective and presents better results for patients.

This personalized medicine model, through preventive pharmacogenomic testing, is carried out on a large scale in seven existing European settings (Netherlands, Spain, United Kingdom, Italy, Austria, Greece and Slovenia). In Spain, the project is coordinated by the researcher from the Biosanitary Research Institute of Granada Cristina Lucía Dávila and directed by the director of the Granada Pharmacy clinical management unit, José Cabeza, who explains that numerous studies have shown that some genetic variations in the genes that encode drug transporters and enzymes that metabolize drugs affect their bioavailability, resulting in under or overdose of patients.

This in turn increases the risk of non-response to medications and the occurrence of adverse reactions. Since 2005, the Dutch Pharmacogenetics Working Group has developed clinical practice guidelines that collect information on XNUMX genes that affect drug metabolism and dose recommendations.

In our country, the recruitment of patients will be carried out at the Complejo Hospitalario Universitario de Granada and the processing of samples and genotyping at the Pfizer Center-University of Granada-Junta de Andalucía for Genomics and Oncology Research (GENYO). 

This project has received funding from the European Union's Horizon 2020 Research and Innovation Program under Grant Agreement No 668353